TMEM97: A Potential Drug Target for Meningiomas (G27346)

Target Name: TMEM97

NCBI ID: G27346

TMEM97

TMEM97: A Potential Drug Target for Meningiomas

TMEM97 (Meningioma-associated protein 30) is a protein that is expressed in various tissues, including the brain, spleen, heart, and testes. It is also known as meningioma-associated protein 30 (MAP30) and has been identified as a potential drug target in the treatment of meningiomas, which are aggressive and often fatal brain tumors.

The protein is made by the brain and is found in various forms in different tissues. It is a member of the transmembrane protein family and is expressed in a variety of tissues, including the brain, spleen, heart, and testes. It is also involved in the development and progression of meningiomas, which are aggressive and often deadly brain tumors.

One of the key functions of TMEM97 is its role in the development of meningiomas. Studies have shown that TMEM97 is involved in the development and progression of meningiomas by promoting the growth and survival of cancer cells. It is also involved in the formation of new blood vessels, which is a critical source of oxygen and nutrients for cancer cells.

In addition to its role in the development and progression of meningiomas, TMEM97 is also involved in the regulation of cell signaling pathways. It is a known regulator of theNotch signaling pathway, which is involved in the development and progression of many types of cancer. is also involved in the regulation of the TGF-β pathway, which is involved in the regulation of cell growth and differentiation.

Given its involvement in the development and progression of meningiomas, TMEM97 is a promising drug target for the treatment of these aggressive tumors. Preclinical studies have shown that inhibiting TMEM97 using small molecules or antibodies can significantly reduce the growth and survival of meningioma cells.

In addition to its potential as a drug target, TMEM97 is also a potential biomarker for the diagnosis and prognosis of meningiomas. The expression of TMEM97 has been shown to be elevated in the brains of patients with meningiomas, and its levels have been used as a biomarker for the diagnosis of these tumors. This suggests that TMEM97 may be a useful diagnostic tool for meningiomas.

Furthermore, TMEM97 has also been shown to be involved in the regulation of cellular processes that are important for the development and progression of many types of cancer. This suggests that it may be a useful target for the development of new anti-cancer drugs.

In conclusion, TMEM97 is a protein that is expressed in various tissues and is involved in the development and progression of meningiomas. It is also a potential drug target and biomarker for these aggressive tumors. Further research is needed to fully understand its role in the development and treatment of meningiomas.

Protein Name: Transmembrane Protein 97

Functions: Intracellular orphan receptor that binds numerous drugs and which is highly expressed in various proliferating cancer cells (PubMed:28559337). Corresponds to the sigma-2 receptor, which is thought to play important role in regulating cell survival, morphology and differentiation (PubMed:23922215, PubMed:25620095). Under investigation for its potential diagnostic and therapeutic uses (PubMed:23922215, PubMed:25620095). May play a role as a regulator of cellular cholesterol homeostasis (PubMed:19583955). May function as sterol isomerase (PubMed:25566323). May alter the activity of some cytochrome P450 proteins (PubMed:22292588)

The "TMEM97 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMEM97 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets